BOSTON ( TheStreet) -- Human Genome Sciences (HGSI), Dendreon (DNDN) and MELA Sciences (MELA - Get Report) each face off against regulators and independent experts next week in a series of separate meetings that will play an important determining role in the future of their respective drugs and medical devices.
The big meetings will unfold over three straight days next week, Nov. 16-18, but the action actually kicks off Friday. What follows is a day-by-day calendar to help investors interesting in following these important meetings.
Friday, Nov. 12
Stock to watch: Human Genome Sciences
The U.S. Food and Drug Administration is expected to post briefing documents for next week's advisory panel set up to review Human Genome's lupus drug Benlysta. These FDA documents will include the agency's review of the drug and the voting questions that will be posed to the panel's independent experts.The FDA typically posts advisory panel briefing documents in the morning. You'll want to check frequently the FDA's Arthritis Drugs Advisory Committee web site starting around 7:30 am. Traders will be keying on what the FDA says about Benlysta in its review, which will, of course, impact Human Genome Science's stock price. Tuesday, Nov. 16
Stocks to watch: Human Genome Sciences and MELA Sciences The FDA convenes an advisory panel to review Human Genome Science's lupus drug Benlysta, beginning at 8 am. Expect a trading halt in Human Genome all day, which may or may not extend into the after-hours trading session depending on the length of the panel meeting. I will be live-blogging the Benlysta panel all day, including a real-time, play-by-play of the panel's votes on whether to recommend the drug's approval, which will likely come towards the mid-afternoon. A live link to my blog will be available on Tuesday morning, starting around 7:45 am ET, but you can register now for an email reminder below. I previewed the Benlysta FDA panel on Monday, which outlines the issues and questions that will likely be raised about the drug's efficacy and safety. Also on Tuesday, the FDA is expected to post briefing documents for the advisory panel set up to review MELA Sciences' skin cancer detection device MELAFind. Like above, these briefing documents will include the FDA's review of MELAFind and will clearly have a big impact on MELA Sciences trading. Check the FDA's General and Plastic Surgery Devices Panel web site early Tuesday morning for the MELAFind briefing documents. Wednesday Nov. 17
Stock to watch: Dendreon Investor focus will shift from FDA to the Center for Medicare and Medicaid Services (CMS), which is conducting a "national coverage analysis" to determine reimbursement coverage for on-label and off-label use of Dendreon's prostate cancer vaccine Provenge.